tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Pancytopenia D010198 6 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Brain Edema D001929 20 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sewing KF Pharmacokinetics, dosing principles, and blood level monitoring of FK506. 1994 Transplant. Proc. pmid:7527962
Klintmalm GB et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679828
Wachtman GS et al. Biologics and donor bone marrow cells for targeted immunomodulation in vascularized composite allotransplantation: a translational trial in swine. 2011 Transplant. Proc. pmid:22099837
Venkataramanan R et al. Pharmacokinetics of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721261
Washburn WK et al. Tacrolimus rescue therapy for renal allograft rejection refractory to cyclosporine-based immunosuppression. 1996 Transplant. Proc. pmid:8623214
Fitzsimmons WE et al. Demographic considerations in tacrolimus pharmacokinetics. 1998 Transplant. Proc. pmid:9636552
Jang HJ et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis. 2000 Transplant. Proc. pmid:11119904
Chakkera HA et al. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375287
Burke GW et al. Tacrolimus-related microangiopathy in kidney and simultaneous pancreas-kidney recipients: evidence of endothelin and cytokine involvement. 1998 Transplant. Proc. pmid:9532223
Tian Ch et al. B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375291
Sahar G et al. Glucose metabolism in heart transplant recipients treated with FK506 or cyclosporine. 2003 Transplant. Proc. pmid:12644092
Vilalta R et al. Delayed graft function is reduced with antithymocyte globulin induction in pediatric kidney transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715923
Imventarza O et al. Renal transplantation in baboons under FK 506. 1990 Transplant. Proc. pmid:1689903
Sgrosso JL et al. Tacrolimus pharmacokinetics in heart transplant. 2002 Transplant. Proc. pmid:11959225
Žilinská Z et al. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. 2016 Transplant. Proc. pmid:27788794
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Schreiber SL et al. Immunophilin-ligand complexes as probes of intracellular signaling pathways. 1991 Transplant. Proc. pmid:1721293
Maggard M et al. Incidence of acute rejection in African-American liver transplant recipients. 1998 Transplant. Proc. pmid:9636607
Yamaguchi M et al. FK 506 significantly improves transferred insulin gene expression in total pancreatectomized dogs. 2000 Transplant. Proc. pmid:11120255
Butt TR et al. Molecular basis of immunosuppressive drug action: regulation of steroid receptor-mediated transcription by FK 506. 1996 Transplant. Proc. pmid:8623486
Mueller AR et al. Influence of immunosuppression on patient outcome after liver transplantation. 1998 Transplant. Proc. pmid:9636608
Yoshida S et al. Combination therapy with FK 506 and RS61443 for rejection following allogeneic small bowel transplantation in rats. 2000 Transplant. Proc. pmid:11120262
Morales JM et al. Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid. 1999 Transplant. Proc. pmid:10576051
Jordan ML et al. Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up. 1999 Transplant. Proc. pmid:10576052
Nishikawa S et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. 2009 Transplant. Proc. pmid:19917404
Pérez-Flores I et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus. 2010 Transplant. Proc. pmid:20970565
Marzorati S et al. Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device. 2009 Jan-Feb Transplant. Proc. pmid:19249555
Spada M et al. Morphology of acute rejection and observation of lymphoproliferative hyperplastic reaction in FK 506 treated pigs after small bowel transplantation. 1994 Transplant. Proc. pmid:7518142
Kai N et al. A study on the timing of immunologic priming in autoimmune insulitis in NOD mice. 1992 Transplant. Proc. pmid:1376511
Langrehr JM et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. 1995 Transplant. Proc. pmid:7533373
Nakata S et al. Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. 1991 Transplant. Proc. pmid:1721325
Liu B et al. Single-center experience: tacrolimus and mycophenolate mofetil in early stage of kidney transplantation with liver dysfunction. 2003 Transplant. Proc. pmid:12591396
Nakamura K et al. Renal transplant recipient experiencing pneumatosis cystoides intestinalis: a case report. 2003 Transplant. Proc. pmid:12591410
Iwahori T et al. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. 2005 Transplant. Proc. pmid:15919450
Takeuchi H et al. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. 2005 Transplant. Proc. pmid:15919452
Sarvary E et al. De novo Prograf versus de novo Advagraf: are trough level profile curves similar? Transplant. Proc. pmid:25131131
Varo E et al. Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy. 2002 Transplant. Proc. pmid:12176481
Winkler M et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. 1995 Transplant. Proc. pmid:7533433
Odoul F et al. Massive ingestion of tacrolimus in a young liver transplant patient. 1998 Transplant. Proc. pmid:9865375
Van Thiel DH et al. Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1721357
Weber M et al. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. 1997 Transplant. Proc. pmid:9414883
Deniz H et al. Inhibition of the renin angiotensin system decreases fibrogenic cytokine expression in tacrolimus nephrotoxicity in rats. 2006 Transplant. Proc. pmid:16549154
Fisniku O et al. Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles. 2005 Transplant. Proc. pmid:15919518
Jiménez O et al. Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation. 2003 Transplant. Proc. pmid:12962758
Cotovio P et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. 2013 Transplant. Proc. pmid:23622631
Cronin DC et al. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal. 1997 Feb-Mar Transplant. Proc. pmid:9123010
Teebken OE et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients. 2002 Transplant. Proc. pmid:12072335
Rossi G et al. Results of orthotopic liver-small bowel transplantation in the pig using different immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907932
Burke GW et al. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection. 2002 Transplant. Proc. pmid:12176505
Meçule A et al. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen. 2011 Transplant. Proc. pmid:21620042
Kaufman DB et al. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. 1999 Feb-Mar Transplant. Proc. pmid:10083261
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Schmidt RJ et al. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721390
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Tze WJ et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. 1991 Transplant. Proc. pmid:1721391
Personett HA et al. Impact of molecular adsorbent recirculating system therapy on tacrolimus elimination: a case report. 2014 Transplant. Proc. pmid:25017243
Guo Z et al. Leflunomide, a potential immunosuppressant for pancreatic islet transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123314
Gerbase MW et al. Low doses of mycophenolate mofetil with low doses of tacrolimus prevent acute rejection and long-term function loss after lung transplantation. 2001 Transplant. Proc. pmid:11377481
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Walgenbach KJ et al. Immunocytes of composite tissue allografts express elevated levels of TGF beta mRNA and protein during chronic rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123418
Sifontis NM et al. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. 2002 Transplant. Proc. pmid:12176554
Gerhardt U et al. High QT dispersion in tacrolimus-treated kidney transplant recipients. 2001 Transplant. Proc. pmid:11377482
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Toda F et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. 2002 Transplant. Proc. pmid:12176555
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Ju MK et al. A 6-month, open-label, multicenter clinical study in Korean de novo renal transplant patients evaluating the efficacy, safety, and tolerance of myfortic concomitantly used with tacrolimus. 2012 Transplant. Proc. pmid:22310600
Ciancio G et al. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267169
Boggs S et al. FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. 1991 Transplant. Proc. pmid:1721420
Ogawa N et al. Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. 1996 Transplant. Proc. pmid:8658710
Pan D et al. Tacrolimus-associated Diffuse Gastrointestinal Ulcerations and Pathergy: A Case Report. Transplant. Proc. pmid:28104141
Dick TB et al. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients. 2011 Transplant. Proc. pmid:21911143
Zucker MJ et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. 2005 Transplant. Proc. pmid:15964386
Gridelli B et al. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723311
Kiberd BA et al. Impact of mycophenolate mofetil loading on drug exposure in the early posttransplant period. 2005 Transplant. Proc. pmid:15964408
Hummel AD et al. Application of artificial neural networks in renal transplantation: classification of nephrotoxicity and acute cellular rejection episodes. 2010 Transplant. Proc. pmid:20304167
Wiseman AC et al. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. 2003 Transplant. Proc. pmid:12742482
Holt DW et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. 2003 Transplant. Proc. pmid:12742490
Webb NJ et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. 2002 Transplant. Proc. pmid:12176639
Collin C et al. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. 2010 Transplant. Proc. pmid:21168693
Sundberg AK et al. Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: a focus on opinions and outcomes. 2002 Transplant. Proc. pmid:12176640
Li ZY et al. Analytical performance of the Abbott Architect i2000 tacrolimus assay in Chinese patients after renal transplantation. 2010 Transplant. Proc. pmid:21168731
Veroux M et al. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. 2006 Transplant. Proc. pmid:16757256
Mohamed MA et al. TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267336
Shokouh-Amiri MH et al. The importance of early prevention of renal dysfunction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267345
Murio JE et al. Compassionate use of FK 506 in liver transplantation. 1995 Transplant. Proc. pmid:7544501
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients. 1999 Transplant. Proc. pmid:10500604
Reiner J et al. After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. 2016 Transplant. Proc. pmid:27109987
Thomson AW et al. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. 1991 Transplant. Proc. pmid:1721452
García González M et al. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. 1999 Transplant. Proc. pmid:10500620
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
Immunosuppression: FK506. 1988 Transplant. Proc. pmid:2450415
Todo S et al. Effect of FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450416
Yoshimura R et al. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. 1991 Transplant. Proc. pmid:1703686
Miyagawa S et al. Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. 1991 Transplant. Proc. pmid:1703687
Kinukawa T et al. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. 1998 Transplant. Proc. pmid:9636498
Morris-Stiff G et al. Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636499
Alak AM and Moy S Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. 1997 Transplant. Proc. pmid:9270821
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822